BG106882A - Ep4 receptor selective agonists in the treatment of osteoporosis - Google Patents
Ep4 receptor selective agonists in the treatment of osteoporosisInfo
- Publication number
- BG106882A BG106882A BG106882A BG10688202A BG106882A BG 106882 A BG106882 A BG 106882A BG 106882 A BG106882 A BG 106882A BG 10688202 A BG10688202 A BG 10688202A BG 106882 A BG106882 A BG 106882A
- Authority
- BG
- Bulgaria
- Prior art keywords
- receptor selective
- bone
- osteoporosis
- agonists
- treatment
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 4
- 101150109738 Ptger4 gene Proteins 0.000 title abstract 3
- 208000001132 Osteoporosis Diseases 0.000 title abstract 2
- 206010065687 Bone loss Diseases 0.000 abstract 2
- 210000000988 bone and bone Anatomy 0.000 abstract 2
- 150000003180 prostaglandins Chemical class 0.000 abstract 2
- 208000010392 Bone Fractures Diseases 0.000 abstract 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 201000001245 periodontitis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17135399P | 1999-12-22 | 1999-12-22 | |
| PCT/IB2000/001711 WO2001046140A1 (en) | 1999-12-22 | 2000-11-20 | Ep4 receptor selective agonists in the treatment of osteoporosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG106882A true BG106882A (en) | 2003-02-28 |
Family
ID=22623430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG106882A BG106882A (en) | 1999-12-22 | 2002-06-28 | Ep4 receptor selective agonists in the treatment of osteoporosis |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US6737437B2 (cs) |
| EP (1) | EP1110949B1 (cs) |
| JP (1) | JP2001181210A (cs) |
| KR (1) | KR100419681B1 (cs) |
| CN (1) | CN1413190A (cs) |
| AP (2) | AP2002002555A0 (cs) |
| AT (1) | ATE250575T1 (cs) |
| AU (2) | AU1293101A (cs) |
| BG (1) | BG106882A (cs) |
| BR (1) | BR0016560A (cs) |
| CA (1) | CA2329678A1 (cs) |
| CO (1) | CO5251453A1 (cs) |
| CR (1) | CR6678A (cs) |
| CZ (1) | CZ20022048A3 (cs) |
| DE (1) | DE60005471T2 (cs) |
| DK (1) | DK1110949T3 (cs) |
| EA (1) | EA005293B1 (cs) |
| EE (1) | EE200200355A (cs) |
| ES (1) | ES2204458T3 (cs) |
| GE (1) | GEP20043203B (cs) |
| HR (1) | HRP20020537A2 (cs) |
| HU (1) | HUP0005001A3 (cs) |
| IL (1) | IL140325A0 (cs) |
| IS (1) | IS6388A (cs) |
| MA (1) | MA26852A1 (cs) |
| MX (1) | MXPA02006322A (cs) |
| NO (1) | NO20022925L (cs) |
| OA (1) | OA12117A (cs) |
| PE (1) | PE20010953A1 (cs) |
| PL (1) | PL356662A1 (cs) |
| PT (1) | PT1110949E (cs) |
| SK (1) | SK8552002A3 (cs) |
| TR (2) | TR200201643T2 (cs) |
| UA (1) | UA72293C2 (cs) |
| WO (1) | WO2001046140A1 (cs) |
| ZA (1) | ZA200007694B (cs) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010056060A1 (en) * | 2000-02-07 | 2001-12-27 | Cameron Kimberly O. | Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
| ES2291361T3 (es) | 2000-11-27 | 2008-03-01 | Pfizer Products Inc. | Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis. |
| KR20040015364A (ko) * | 2001-07-16 | 2004-02-18 | 에프. 호프만-라 로슈 아게 | Ｅｐ4 수용체 작용물질로서의 프로스타글란딘 유사체 |
| DK1408961T3 (da) * | 2001-07-16 | 2007-11-05 | Hoffmann La Roche | 2 pyrrolidon-derivater som prostanoide agonister |
| CN1893977B (zh) * | 2001-07-23 | 2012-12-05 | 小野药品工业株式会社 | 以ep4激动剂为活性成分的治疗与骨质损失有关的疾病的药物 |
| CN101921220B (zh) | 2001-07-23 | 2013-05-22 | 小野药品工业株式会社 | 治疗与骨质损失有关的疾病的含有ep4激动剂作为活性成分的药物组合物 |
| EP1452178A1 (en) * | 2001-11-12 | 2004-09-01 | Ono Pharmaceutical Co., Ltd. | Persistent filmy preparation for topical administration containing prostaglandin derivative |
| EP1453503A4 (en) * | 2001-12-03 | 2005-03-30 | Merck & Co Inc | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS |
| US20040254230A1 (en) * | 2001-12-03 | 2004-12-16 | Ogidigben Miller J. | Method for treating ocular hypertension |
| US7335680B2 (en) | 2001-12-20 | 2008-02-26 | Laboratoires Serono Sa | Pyrrolidine derivatives as prostaglandin modulators |
| CN1653046A (zh) | 2002-03-05 | 2005-08-10 | 小野药品工业株式会社 | 8－氮杂前列腺素衍生化合物以及包含该化合物作为活性成分的药物 |
| AU2003209571A1 (en) * | 2002-03-18 | 2003-09-29 | Pfizer Products Inc. | Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension |
| AU2011202937B2 (en) * | 2002-05-14 | 2012-06-07 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| US6573294B1 (en) * | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| JP4766875B2 (ja) | 2002-06-06 | 2011-09-07 | メルク フロスト カナダ リミテツド | Ｅｐ４受容体作動薬、組成物及びその方法 |
| JP4754820B2 (ja) | 2002-06-10 | 2011-08-24 | メルク セローノ ソシエテ アノニム | プロスタグランジン作動薬としてのγラクタムおよびその使用 |
| EP1563846B1 (en) | 2002-10-10 | 2012-08-29 | Ono Pharmaceutical Co., Ltd. | Endogenous repair factor production promoters |
| JP2006510742A (ja) | 2002-11-08 | 2006-03-30 | メルク エンド カムパニー インコーポレーテッド | 高眼圧治療用眼科組成物 |
| US7196082B2 (en) | 2002-11-08 | 2007-03-27 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
| US7053085B2 (en) | 2003-03-26 | 2006-05-30 | Merck & Co. Inc. | EP4 receptor agonist, compositions and methods thereof |
| CN1735597A (zh) * | 2003-01-10 | 2006-02-15 | 霍夫曼-拉罗奇有限公司 | 作为前列腺素激动剂的2－哌啶酮衍生物 |
| EP1586564B1 (en) * | 2003-01-21 | 2012-11-28 | Ono Pharmaceutical Co., Ltd. | 8-azaprostaglandin derivatives and medicinal uses thereof |
| AU2004216857A1 (en) | 2003-03-03 | 2004-09-16 | Laboratoires Serono Sa | G-lactam derivatives as prostaglandin agonists |
| US6734206B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| US6734201B1 (en) * | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents |
| US7179820B2 (en) | 2003-06-06 | 2007-02-20 | Allergan, Inc. | Piperidinyl prostaglandin E analogs |
| US7465755B2 (en) | 2003-07-18 | 2008-12-16 | Laboratoires Serono Sa | Hydrazide derivatives as prostaglandin receptors modulators |
| AU2004268012B2 (en) | 2003-09-02 | 2008-11-20 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| RU2006110625A (ru) | 2003-09-04 | 2006-08-10 | Мерк энд Ко., Инк. (US) | Офтальмические композиции для лечения глазной гипертензии |
| CA2537430A1 (en) | 2003-09-04 | 2005-03-24 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| WO2005027931A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist |
| EP1723132A1 (en) | 2004-02-12 | 2006-11-22 | Asterand Uk Limited | Ep2 receptor agonists |
| WO2006020003A2 (en) | 2004-07-20 | 2006-02-23 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| AU2005313380A1 (en) | 2004-12-06 | 2006-06-15 | Merck Serono Sa | Pyrrolidin-2-one derivatives for use as DP1 receptor agonists |
| US7531533B2 (en) | 2005-01-27 | 2009-05-12 | Asahi Kasei Pharma Corporation | 6-Membered heterocyclic compound and use thereof |
| US20090074844A1 (en) | 2005-04-28 | 2009-03-19 | Ono Pharmaceutical Co., Ltd. | Trenadermal absorption preparation |
| KR100686186B1 (ko) * | 2005-06-13 | 2007-02-26 | 영진종합건설 주식회사 | 교량용 배수 구조물 |
| CA2618486A1 (en) | 2005-08-09 | 2007-02-15 | Asterand Uk Limited | Ep2 receptor agonists |
| WO2008050848A1 (en) | 2006-10-26 | 2008-05-02 | Ono Pharmaceutical Co., Ltd. | Adhesive preparation |
| US9394520B2 (en) | 2006-12-08 | 2016-07-19 | University Of Rochester | Expansion of hematopoietic stem cells |
| EP2220057A4 (en) | 2007-11-14 | 2011-10-12 | Cayman Chem Co | PROSTAGLANDIN E1 AND E2 ANALOGUES FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS |
| CA2738045C (en) | 2010-05-28 | 2019-02-19 | Simon Fraser University | Conjugate compounds, methods of making same, and uses thereof |
| TW201321003A (zh) | 2011-08-02 | 2013-06-01 | Ono Pharmaceutical Co | 左心室擴張機能改善劑 |
| EP3176162B1 (en) | 2012-07-19 | 2020-05-27 | Cayman Chemical Company, Inc. | Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions |
| JP6400479B2 (ja) | 2012-10-29 | 2018-10-03 | 株式会社カルディオ | 肺疾患特異的治療剤 |
| US9676712B2 (en) | 2013-03-15 | 2017-06-13 | Cayman Chemical Company, Inc. | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
| EP2989098B1 (en) * | 2013-03-15 | 2017-05-10 | Cayman Chemical Company, Incorporated | Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions |
| WO2015009991A2 (en) | 2013-07-19 | 2015-01-22 | Cayman Chemical Company, Inc. | Methods, systems, and compositions for promoting bone growth |
| KR20220147691A (ko) | 2013-08-09 | 2022-11-03 | 알데릭스, 인코포레이티드 | 인산염 수송을 억제하기 위한 화합물 및 방법 |
| US9968716B2 (en) | 2013-10-15 | 2018-05-15 | Ono Pharmaceutical Co., Ltd. | Drug-eluting stent graft |
| US10400000B2 (en) | 2015-06-12 | 2019-09-03 | Simon Fraser University | Amide-linked EP4 agonist-bisphosphonate compounds and uses thereof |
| EP3972599B1 (en) | 2019-05-21 | 2025-10-22 | Ardelyx, Inc. | Combination for lowering serum phosphate in a patient |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR897566A (fr) | 1942-08-28 | 1945-03-26 | Bopp & Reuther Gmbh | Machine à rotors |
| US3528961A (en) | 1966-08-16 | 1970-09-15 | Allied Chem | Monoazo dyes from e-caprolactam |
| US3780095A (en) | 1970-04-08 | 1973-12-18 | Byk Gulden Lomberg Chem Fab | Acylated anilino-carboxylic acids and their salts |
| US3987091A (en) | 1973-04-12 | 1976-10-19 | Merck & Co., Inc. | 11,12-secoprostaglandins |
| US4033996A (en) | 1973-04-25 | 1977-07-05 | Merck & Co., Inc. | 8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins |
| SE7414770L (cs) | 1973-12-13 | 1975-06-16 | Merck & Co Inc | |
| DK366475A (da) | 1974-08-30 | 1976-03-01 | Merck & Co Inc | Fremgangsmade til fremstilling af aryloxy- eller arylthioholdige secoprostaglandiner |
| US3991106A (en) | 1974-09-13 | 1976-11-09 | Merck & Co., Inc. | 16-Ethers of 8-aza-9-dioxothia-11,12-seco-prostaglandins |
| US4055596A (en) | 1974-09-13 | 1977-10-25 | Merck & Co., Inc. | 11,12-Seco-prostaglandins |
| US4113873A (en) | 1975-04-26 | 1978-09-12 | Tanabe Seiyaku Co. Ltd. | 8-azaprostanoic acid derivatives |
| DE2528664A1 (de) * | 1975-06-27 | 1977-01-13 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
| IL49325A (en) | 1976-03-31 | 1979-11-30 | Labaz | 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them |
| DE2619638A1 (de) | 1976-05-04 | 1977-11-17 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
| US4177346A (en) | 1976-08-06 | 1979-12-04 | Pfizer Inc. | 1,5-Disubstituted-2-pyrrolidones |
| US4175203A (en) | 1976-12-17 | 1979-11-20 | Merck & Co., Inc. | Interphenylene 11,12-secoprostaglandins |
| US4243678A (en) | 1977-12-30 | 1981-01-06 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Acylhydrocarbylaminoalkanoic acids, compositions and uses |
| DE3000377A1 (de) | 1980-01-07 | 1981-07-09 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel |
| DE3042482A1 (de) | 1980-11-11 | 1982-06-24 | A. Nattermann & Cie GmbH, 5000 Köln | N-benzoyl- (omega) -anilinoalkancarbonsaeuren, -salze und -ester, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
| CA1214170A (fr) | 1981-06-16 | 1986-11-18 | Patrick Choay | Procedes de preparation de nouveaux composes du type arylbenzenesulfonamide |
| AU6427596A (en) * | 1992-04-14 | 1996-10-31 | Alfred Maximillian Stessl | A boat hull |
| TW383306B (en) | 1992-12-22 | 2000-03-01 | Lilly Co Eli | New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol |
| US6426359B1 (en) * | 1996-12-20 | 2002-07-30 | Pfizer Inc. | Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 agonists |
| GB2330307A (en) * | 1998-02-07 | 1999-04-21 | Glaxo Group Ltd | EP4 Receptor antagonists as bone resorption inhibitors |
| EP1121133A1 (en) * | 1998-10-15 | 2001-08-08 | Merck & Co., Inc. | Methods for stimulating bone formation |
| WO2000021532A1 (en) * | 1998-10-15 | 2000-04-20 | Merck & Co., Inc. | Methods for inhibiting bone resorption |
-
2000
- 2000-11-20 GE GEAP20006502A patent/GEP20043203B/en unknown
- 2000-11-20 PL PL00356662A patent/PL356662A1/xx not_active Application Discontinuation
- 2000-11-20 EE EEP200200355A patent/EE200200355A/xx unknown
- 2000-11-20 CN CN00817566A patent/CN1413190A/zh active Pending
- 2000-11-20 EA EA200200505A patent/EA005293B1/ru not_active IP Right Cessation
- 2000-11-20 BR BR0016560-3A patent/BR0016560A/pt not_active IP Right Cessation
- 2000-11-20 TR TR2002/01643T patent/TR200201643T2/xx unknown
- 2000-11-20 OA OA1200200177A patent/OA12117A/en unknown
- 2000-11-20 AU AU12931/01A patent/AU1293101A/en not_active Abandoned
- 2000-11-20 AP APAP/P/2002/002555A patent/AP2002002555A0/en unknown
- 2000-11-20 HR HRP20020537 patent/HRP20020537A2/hr not_active Application Discontinuation
- 2000-11-20 CZ CZ20022048A patent/CZ20022048A3/cs unknown
- 2000-11-20 AP APAP/P/2001/002357A patent/AP2001002357A0/en unknown
- 2000-11-20 UA UA2002065186A patent/UA72293C2/uk unknown
- 2000-11-20 MX MXPA02006322A patent/MXPA02006322A/es active IP Right Grant
- 2000-11-20 WO PCT/IB2000/001711 patent/WO2001046140A1/en not_active Ceased
- 2000-11-20 SK SK855-2002A patent/SK8552002A3/sk unknown
- 2000-12-11 EP EP00311034A patent/EP1110949B1/en not_active Expired - Lifetime
- 2000-12-11 TR TR2003/01841T patent/TR200301841T4/xx unknown
- 2000-12-11 AT AT00311034T patent/ATE250575T1/de not_active IP Right Cessation
- 2000-12-11 DK DK00311034T patent/DK1110949T3/da active
- 2000-12-11 PT PT00311034T patent/PT1110949E/pt unknown
- 2000-12-11 ES ES00311034T patent/ES2204458T3/es not_active Expired - Lifetime
- 2000-12-11 DE DE60005471T patent/DE60005471T2/de not_active Expired - Fee Related
- 2000-12-14 IL IL14032500A patent/IL140325A0/xx unknown
- 2000-12-15 US US09/738,670 patent/US6737437B2/en not_active Expired - Fee Related
- 2000-12-19 PE PE2000001368A patent/PE20010953A1/es not_active Application Discontinuation
- 2000-12-19 KR KR10-2000-0078214A patent/KR100419681B1/ko not_active Expired - Fee Related
- 2000-12-20 ZA ZA200007694A patent/ZA200007694B/xx unknown
- 2000-12-20 AU AU72393/00A patent/AU763983B2/en not_active Ceased
- 2000-12-20 CA CA002329678A patent/CA2329678A1/en not_active Abandoned
- 2000-12-21 HU HU0005001A patent/HUP0005001A3/hu unknown
- 2000-12-22 CO CO00097391A patent/CO5251453A1/es not_active Application Discontinuation
- 2000-12-22 JP JP2000390594A patent/JP2001181210A/ja not_active Ceased
-
2001
- 2001-11-16 US US09/991,585 patent/US6642266B2/en not_active Expired - Fee Related
-
2002
- 2002-05-17 IS IS6388A patent/IS6388A/is unknown
- 2002-06-12 CR CR6678A patent/CR6678A/es not_active Application Discontinuation
- 2002-06-13 MA MA26686A patent/MA26852A1/fr unknown
- 2002-06-18 NO NO20022925A patent/NO20022925L/no not_active Application Discontinuation
- 2002-06-28 BG BG106882A patent/BG106882A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG106882A (en) | Ep4 receptor selective agonists in the treatment of osteoporosis | |
| EA200300379A1 (ru) | Селективные агонисты рецептора ep4 в лечении остеопороза | |
| MY141384A (en) | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | |
| NO20012158L (no) | Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav | |
| ES2311803T3 (es) | Composiciones embolicas de silicie pirogena. | |
| YU18400A (sh) | Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja | |
| AP9801269A0 (en) | Prostaglandin agonists. | |
| NO20062860L (no) | Sammensetning og fremgangsmate for styrking av biologisk tilgjengelighet | |
| PL370373A1 (en) | Substituted piperidines as modulators of the melanocortin receptor | |
| NO20010446L (no) | Substituert anilidforbindelser og metoder | |
| ATE536855T1 (de) | Gewebegerüste zusamensetzungen zur behandlung von zahnerkrankungen | |
| TNSN08396A1 (en) | Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual | |
| BRPI0417621A (pt) | terapia de combinação contìnua com agonistas seletivos do receptor ep4 de prostaglandina e um estrogênio para o tratamento de estados que se apresentem com baixa massa óssea | |
| MX2009006969A (es) | Purificacion de romidepsina. | |
| WO2004050620A3 (en) | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | |
| NO20061845L (no) | Fenyl-piperazinderivater som modulatorer for muskarine reseptorer | |
| CA2334257A1 (en) | Treatment of osteoporosis with ep2/ep4 receptor selective agonists | |
| MXPA03007413A (es) | Composicion y metodo para tratar enfermedades inflamatorias. | |
| NO20044881L (no) | Acyl-3-karboksyfenylureaderivater, fremstillingsfremgangsmate og anvendelse derav | |
| AU2003251729A8 (en) | Use of antibodies against flt-1 for the treatment of osteoporosis | |
| PL366988A1 (en) | Gelling sugar and method for producing the same | |
| CR6952A (es) | Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis | |
| MY139532A (en) | Process for making bar composition having little or no efflorescence |